Section 329-16 - Schedule II(a) The controlled substances listed in this section are included in schedule II.(b) Any of the following substances, except those narcotic drugs listed in other schedules, whether produced directly or indirectly by extraction from substances of vegetable origin, or independently by means of chemical synthesis, or by combination of extraction and chemical synthesis: (1) Opium and opiate, and any salt, compound, derivative, or preparation of opium or opiate, excluding apomorphine, thebaine-derived butorphanol, dextrorphan, nalbuphine, nalmefene, naloxegol, naloxone, and naltrexone, and their respective salts, but including the following: (H) Etorphine hydrochloride;(2) Any salt, compound, isomer, derivative, or preparation thereof which is chemically equivalent or identical with any of the substances referred to in paragraph (1), but not including the isoquinoline alkaloids of opium;(3) Opium poppy and poppy straw;(4) Coca leaves and any salt, compound, derivative, or preparation of coca leaves, and any salt, compound, derivative, or preparation thereof which is chemically equivalent or identical with any of these substances, but not including decocanized coca leaves or extractions which do not contain cocaine or ecgonine; cocaine or any salt or isomer thereof; and(5) Concentrate of poppy straw (the crude extract of poppy straw in either liquid, solid, or powder form that contains the phenanthrene alkaloids of the opium poppy).(c) Any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, whenever the existence of these isomers, esters, ethers, and salts is possible within the specific chemical designation: (5) Bulk Dextropropoxyphene (nondosage form);(11) Levo-alphacetylmethadol (LAAM);(16) Methadone-Intermediate, 4-cyano-2-dimethylamino-4, 4-diphenyl butane;(17) Moramide-Intermediate, 2-methyl-3-morpholino-1, 1-diphenyl-propane-carboxylic acid;(18) Oliceridine, including the free base form, and its salts, to include the fumarate salt, by definition;(19) Pethidine (Meperidine);(20) Pethidine-Intermediate-A, 4-cyano-1-methyl-4-phenylpiperidine;(21) Pethidine-Intermediate-B, ethyl-4-phenylpiperidine-4-carboxylate;(22) Pethidine-Intermediate-C, 1-methyl-4-phenylpiperidine-4-carboxylic acid;(d) Depressants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a depressant effect on the central nervous system, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, unless specifically excepted, whenever the existence of these isomers, esters, ethers, and salts is possible within the specific chemical designation: (e) Stimulants. Any material, compound, mixture, or preparation which contains any quantity of the following substances having a danger or probable danger associated with a stimulant effect on the central nervous system: (1) Amphetamine, its salts, optical isomers, and salts of its optical isomers;(2) Any substance which contains any quantity of methamphetamine, including its salts, isomers, and salts of isomers;(3) Phenmetrazine and its salts;(5) Lisdexamfetamine, its salts, isomers, and salts of its isomers.(f) Immediate precursor. Unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances:(1) Immediate precursor to amphetamine and methamphetamine: (A) Phenylacetone, phenyl-2-propanone(P2P), benzyl methyl ketone, methyl benzyl ketone;(2) Immediate precursors to phencyclidine (PCP): (A) 1-phenylcyclohexylamine; or(B) 1-piperidinocyclohexanecarbonitrile(PCC); or(3) Immediate precursor to Fentanyl:(A) 4-anilino-N-phenethyl-4-piperidine (ANPP); or(B) N-phenyl-N-(piperidin-4-yl)propionamide (norfentanyl).(g) Hallucinogenic substances, unless listed in another schedule, shall include: (2) Dronabinol (-)-delta-9-trans tetrahydrocannabinol in an oral solution in a drug product approved for marketing by the United States Food and Drug Administration.Amended by L 2022, c 106,§ 2, eff. 6/17/2022.Amended by L 2021, c 233,§ 2, eff. 7/6/2021.Amended by L 2018, c 190,§ 2, eff. 7/10/2018.Amended by L 2018, c 152,§ 1, eff. 7/9/2018.Amended by L 2017, c 155,§ 2, eff. 7/10/2017.Amended by L 2013, c 48,§ 2, eff. 4/24/2013.Amended by L 2012, c 29, § 2, eff. 4/19/2012.Amended by L 2011, c 73, § 2, eff. 7/1/2011.L 1972, c 10, pt of §1 and am c 114, §2(2); am L 1974, c 217, §2; am L 1975, c 26, §1; am L 1978, c 68, §3; am L 1979, c 194, §2; am L 1981, c 125, §§1, 2; am L 1984, c 166, §2; am L 1985, c 150, §2; am L 1987, c 203, §1; am L 1988, c 59, §2; am L 1990, c 138, §4; am L 1991, c 159, §7; am L 1995, c 122, §2; am L 1997, c 356, §2; am L 2000, c 98, §§2, 3; am L 2001, c 203, §3; am L 2002, c 165, §1; am L 2003, c 151, §3; am L 2008, c 119, §4; am L 2009, c 117, §§1, 2; am L 2010, c 123, §2 . Method used to prove that capsules of methaqualone hydrochloride contained methaqualone accepted as evidence. 1 H. App. 31, 613 P.2d 919.